Login to Your Account

Abraxis Partners Abraxane, Buys AstraZeneca Portfolio

By Karen Pihl-Carey

Friday, April 28, 2006
A little more than a year after Abraxane gained FDA approval as a treatment for breast cancer, its developer, Abraxis BioScience Inc., has signed a co-promotion agreement with AstraZeneca plc, essentially doubling the promotional investment of the product. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription